Trilawil  is an oral chelating agent used primarily for the treatment of Wilson’s disease, a genetic disorder characterized by excess copper accumulation in the liver, brain, and other organs. It is often prescribed for patients who cannot tolerate Penicillamine, another copper-chelating medication. Trientine binds copper in the body and helps eliminate it through the urine, thereby reducing copper-related toxicity.

Mechanism of Action

• Trientine binds free copper ions in the bloodstream, forming a stable, non-toxic complex.

• The copper-trientine complex is then excreted through the urine, lowering total body copper.

• By reducing copper accumulation, it prevents liver damage, neurological symptoms, and other complications of Wilson’s disease.

  Uses

  • Treatment of Wilson’s disease (copper overload).

  • Used in patients who are intolerant to Penicillamine.

  • Helps prevent liver damage and neurological complications caused by copper accumulation.

  • Maintenance therapy to control copper levels long-term.

    Adverse Effects

    • Nausea, vomiting, or abdominal discomfort

    • Fatigue or weakness

    • Mild rash or skin irritation

    • Joint or muscle pain